Plasminogen activator inhibitor-1 gene polymorphism and colorectal cancer risk and prognosis

Cancer Letters

Volumn 189, Issue 2, 2003, Pages 189-196

  Loktionov, Alexandre ^a   Watson, Mark A ^b   Stebbings, William S L ^b   Speakman, Chris T M ^b   Bingham, Sheila A ^a  

^a WELLCOME TRUST SANGER INSTITUTE   (United Kingdom)

^b NORFOLK AND NORWICH UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

Colon tumours; Genotype; Plasminogen activator inhibitor 1

Indexed keywords

PLASMINOGEN ACTIVATOR INHIBITOR 1;

ADULT; ARTICLE; CANCER INVASION; CANCER RISK; COLORECTAL CANCER; CONTROLLED STUDY; FEMALE; GENE; GENETIC POLYMORPHISM; GENETIC TRANSCRIPTION; GENOTYPE; HOMOZYGOSITY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; METASTASIS; PRIORITY JOURNAL; PROGNOSIS; PROMOTER REGION; PROTEIN DEGRADATION; TISSUE LEVEL;

ADENOCARCINOMA; AGED; CHROMOSOMES, HUMAN, PAIR 7; COLORECTAL NEOPLASMS; ENGLAND; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; NEOPLASM PROTEINS; PLASMINOGEN ACTIVATOR INHIBITOR 1; POLYMORPHISM, GENETIC; PROGNOSIS; PROMOTER REGIONS (GENETICS); SMOKING; TRANSCRIPTION, GENETIC;

INSERTION SEQUENCES;

EID: 0037469081     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-3835(02)00556-6     Document Type: Article

References (29)

1. Vineis P., Malats N., Lang M., d'Errico A., Caporaso N., Cuzick J., Boffetta P. Metabolic polymorphisms and susceptibility to cancer. IARC Sci. Publ. 1999;IARC, Lyon.
2. Danø K., Rømer J., Nielsen B.S., Bjørn S., Pyke C., Rygaard J., Lund L.R. Cancer invasion and tissue remodeling - Cooperation of protease systems and cell types. APMIS. 107:1999;120-127.
3. Andreasen P.A., Kjøller L., Christensen L., Duffy M.J. The urokinase-type plasminogen activator system in cancer metastasis: a review. Int. J. Cancer. 72:1997;1-22.
4. Abe J., Urano T., Konno H., Erhan Y., Tanaka T., Nishino N., Takada A., Nakamura S. Larger and more invasive colorectal carcinoma contains larger amounts of plasminogen activator inhibitor type 1 and its relative ratio over urokinase receptor correlates well with tumour size. Cancer. 86:1999;2602-2611.
5. Jänicke F., Prechtl A., Thomssen C., Harbeck N., Meisner C., Untch M., Sweep C.G.J.F., Selbmann H.-C., Graeff H., Schmitt M. Randomized adjuvant chemotherapy trial in high-risk, lymph node-negative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen activator inhibitor type 1. J. Natl. Cancer Inst. 93:2001;913-920.
6. Fredstorp-Lidebring M., Bendahl P.O., Brunner N., Casslen B., Hogberg T., Langstrom-Einarsson E., Willen R., Perno M. Urokinase plasminogen activator and its inhibitor PAI-1, in association with progression-free survival in early stage endometrial cancer. Eur. J. Cancer. 37:2001;2339-2348.
7. Nielsen H.J., Pappot H., Christensen I.J., Brünner N., Thorlacius-Ussing O., Moesgaard F., Danø K., Grondahl-Hansen J. Association between plasma concentrations of plasminogen activator inhibitor-1 and survival in patients with colorectal cancer. Br. Med. J. 316:1998;829-830.
8. Klinger K.W., Winqvist R., Riccio A., Andreasen P.A., Sartorio R., Nielsen L.S., Stuart N., Stanislovitis P., Watkins P., Douglas R., Grzeschik K.H., Alitalo K., Blasi F., Danø K. Plasminogen activator inhibitor type 1 gene is located at region q21.3-q22 of chromosome 7 and genetically linked with cystic fibrosis. Proc. Natl. Acad. Sci. USA. 84:1987;8548-8552.
9. Bosma P.J., van den Berg E.A., Kooistra T., Siemieniak D.R., Slightom J.L. Human plasminogen activator inhibitor-1 gene. J. Biol. Chem. 263:1988;9129-9141.
10. Dawson S.J., Wiman B., Hamsten A., Green F., Humphries S., Henney A.M. The two allele sequences of a common polymorphism in the promoter of the plasminogen activator inhibitor-1 (PAI-1) gene respond differently to IL-1 in Hep G2 cells. J. Biol. Chem. 268:1993;10739-10745.
11. Eriksson P., Kallin B., van't-Hooft F.M., Båvenholm P., Hamsten A. Allele-specific increase in basal transcription of the plasminogen-activator inhibitor 1 gene is associated with myocardial infarction. Proc. Natl. Acad. Sci. USA. 92:1995;1851-1855.
12. Reiner A.P., Siscovick D.S., Rosendaal F.R. Hemostatic risk factors and arterial thrombotic disease. Thromb. Haemostasis. 85:2001;584-595.
13. Turkmen B., Schmitt M., Schmalfeldt B., Trommler P., Hell W., Creutzburg S., Graeff H., Magdolen V. Mutational analysis of the genes encoding urokinase-type plasminogen activator (uPA) and its inhibitor PAI-1 in advanced ovarian cancer. Electrophoresis. 18:1997;686-689.
14. Smolarz B., Blasiak J. Plasminogen activator inhibitor-1 promoter 4G/5G genotype in subjects with breast cancer. Biomed. Lett. 60:1999;97-105.
15. Smolarz B., Blasiak J., Kulig A., Romanowicz-Makowska H., Dziki A., Ulanska J., Pander J. T.Szewczyk, Plasminogen activator inhibitor-1 (PAI-1) levels and gene promoter polymorphism in subjects with colorectal cancer. J. Exp. Clin. Cancer Res. 22:2001;48-51.
16. Herszènyi L., Plebani M., Carraro P., DePaoli M., Rovenori G., Cardin R., Tulassay Z., Naccarato R., Farinati F. The role of cysteine and serine proteases in colorectal carcinoma. Cancer. 86:1999;1135-1142.
17. Atkin W.S., Hart A., Edwards R., McIntyre P., Aubrey P., Wardle J., Sutton S., Cuzick J., Northover J.M.A. Uptake, yield of neoplasia, and adverse effects of flexible sigmoidoscopy screening. Gut. 42:1998;560-565.
18. Loktionov A., Watson M.A., Gunter M., Stebbings W.S.L., Speakman C.T.M., Bingham S.A. Glutathione-S-transferase gene polymorphisms in colorectal cancer patients: interaction between GSTM1 and GSTM3 allele variants as a risk-modulating factor. Carcinogenesis. 22:2001;1053-1060.
19. Winawer S.J., Fletcher R.H., Miller L., Godlee F., Stolar M.H., Mulrow C.D., Woolf S.H., Glick S.N., Ganiats T.G., Bond J.H., Rosen L., Zapka J.G., Olsen S.J., Giardello F.N., Sisk J.E., van Antwerp R., Brown-Davis C., Marciniak D.A., Mayer R.J. Colorectal cancer screening: clinical guidelines and rationale. Gastroenterology. 112:1997;594-642.
20. Deans G.T., Parks T.G., Rowlands B.J., Spence R.A.J. Prognostic factors in colorectal cancer. Br. J. Surg. 79:1992;608-613.
21. Gervez P., Bouzourene H., Cerottini J.-P., Chaubert P., Benhattar J., Secic M., Wexner S., Givel J.-C., Belin B. Dukes B colorectal cancer: distinct genetic categories and clinical outcome based on proximal or distal tumour location. Dis. Colon Rectum. 44:2001;364-373.
22. Lindblom A. Different mechanisms in the tumorigenesis of proximal and distal colon cancers. Curr. Opin. Oncol. 13:2001;63-69.
23. Isogai C., Laug W.E., Shimada H., Declerck P.J., Stins M.F., Durden D.L., Erdreich-Epstein A., DeClerck Y.A. Plasminogen activator inhibitor-1 promotes angiogenesis by stimulating endothelial cell migration toward fibronectin. Cancer Res. 61:2001;5587-5594.
24. McMahon G.A., Petitclerc E., Stefansson S., Smith E., Wong M.K.K., Westrick R.J., Ginsburg D., Brooks P.C., Lawrence D.A. Plasminogen activator inhibitor-1 regulates tumour growth and angiogenesis. J. Biol. Chem. 276:2001;33964-33968.
25. Devy L., Blacher S., Grignet-Debrus C., Bajou K., Masson V., Gerard R.D., Gils A., Carmeliet G., Carmeliet P., Declerck P.J., Noel A., Foidart J.M. The pro- or antiangiogenic effect of plasminogen activator inhibitor 1 is dose dependent. FASEB J. 16:2002;147-154.
26. Bajou K., Noël A., Gerard R.D., Masson V., Brunner N., Holst-Hansen C., Skobe M., Fusenig N.E., Carmeliet P., Collen D., Foidart J.M. Absence of host plasminogen activator inhibitor 1 prevents cancer invasion and vascularization. Nat. Med. 4:1998;923-928.
27. Gutierrez L.S., Schulman A., Brito-Robinson T., Noria F., Ploplis V.A., Castellino F.J. Tumour development is retarded in mice lacking the gene for urokinase-type plasminogen activator or its inhibitor, plasminogen activator inhibitor-1. Cancer Res. 60:2000;5839-5847.
28. Chazaud B., Ricoux R., Christov C., Plonquet A., Gherardi R.K., Barlovatz-Meimon G. Promigratory effect of plasminogen activator inhibitor-1 on invasive breast cancer cell populations. Am. J. Pathol. 160:2002;237-246.
29. Kwaan H.C., Wang J., Svoboda K., Declerck P.J. Plasminogen activator inhibitor 1 may promote tumour growth through inhibition of apoptosis. Br. J. Cancer. 82:2000;1702-1708.